← Leaderboards
Steven M. Dubinett
Va Greater Los Angeles Healthcare System
$101,089,960
Attributed
$119,271,186
Total exposure
32
Grants
25
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $32.4M · FY2005–25$50M$37.5M$25M$12.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$246,965,378 · 32
VA$0 · 5
By mechanism
UL1$176,999,886 · 9
U01$15,145,096 · 3
T32$14,486,025 · 2
U2C$13,510,386 · 4
P50$13,401,770 · 3
KL2$4,869,367 · 2
Top collaborators
- Marc Elliott Lenburg20 shared
- Avrum E Spira18 shared
- Michael A Teitell17 shared
- Denise R Aberle14 shared
- David Elashoff14 shared
- Tomas Ganz10 shared
- Fenghai Duan7 shared
- Jennifer Ellen Beane4 shared
Most similar at Va Greater Los Angeles Healthcare System
Same institution · by research overlap
Others in their field
Top investigators on “Malignant Neoplasm Of Lung”
- David Heimbrook · Leidos Biomedical Research, Inc.$349,639,893
- Richard K. Wilson · Washington University$202,666,376
- Walter John Curran · Thomas Jefferson University$94,674,902
- Jan C Buckner · Mayo Clinic Coll Of Medicine, Rochester$61,410,512
- Norman Wolmark · Nsabp Foundation, Inc.$54,610,124
- Leonard Freedman · Leidos Biomedical Research, Inc.$50,919,602
Research focus
Malignant Neoplasm Of LungBaseProgramsDesignUniversitiesCohortResearch PersonnelMultidisciplinaryTraining ProgramsLaboratoriesMalignant NeoplasmsInnovationTumorCollaborationsFundingResourcesLungCellsMolecularCessation Of LifeLos AngelesTranslational ResearchMedicineDiagnosis
Grant awards (175)
The Boston University - UCLA Lung Cancer Biomarker Characterization Center$961,799
U2C · FY2025 · CA
Biomarker Development Lab$463,048
U2C · FY2025 · CA · contact PI
UCLA Tumor Immunology Institutional Training Grant$375,626
T32 · FY2025 · CA
Evaluation of PARP7 dependency as a novel therapeutic target for non-small cell lung cancer$0
I01 · FY2025 · VA · contact PI
The Boston University - UCLA Lung Cancer Biomarker Characterization Center$913,695
U2C · FY2024 · CA
Biomarker Development Lab$497,866
U2C · FY2024 · CA · contact PI
UCLA Tumor Immunology Institutional Training Grant$357,202
T32 · FY2024 · CA
UCLA Pulmonary and Critical Care Medicine Training Program$279,387
T32 · FY2024 · HL · contact PI
UCLA Clinical and Translational Science Institute$225,068
UL1 · FY2024 · TR · contact PI
Exosome-mediated mechanisms of metastatic disease in non-small cell lung cancer$0
I01 · FY2024 · VA · contact PI
UCLA Clinical and Translational Science Institute$9,733,673
UL1 · FY2023 · TR · contact PI
The Boston University - UCLA Lung Cancer Biomarker Characterization Center$942,572
U2C · FY2023 · CA
UCLA Pulmonary and Critical Care Medicine Training Program$582,670
T32 · FY2023 · HL · contact PI
UCLA Tumor Immunology Institutional Training Grant$460,343
T32 · FY2023 · CA
Biomarker Development Lab$456,366
U2C · FY2023 · CA · contact PI
UCLA Clinical Translational Science Institute$1
UL1 · FY2023 · TR · contact PI
Exosome-mediated mechanisms of metastatic disease in non-small cell lung cancer$0
I01 · FY2023 · VA · contact PI
UCLA Clinical and Translational Science Institute$9,815,155
UL1 · FY2022 · TR · contact PI
The Boston University - UCLA Lung Cancer Biomarker Characterization Center$718,649
U2C · FY2022 · CA
Novel Computation Methods for the Analysis of Cell-Free DNA Sequence Data$541,133
R01 · FY2022 · CA
UCLA Tumor Immunology Institutional Traning Grant$536,711
T32 · FY2022 · CA
Biomarker Development Lab$502,606
U2C · FY2022 · CA · contact PI
UCLA Pulmonary and Critical Care Medicine Training Program$400,415
T32 · FY2022 · HL · contact PI
Exosome-mediated mechanisms of metastatic disease in non-small cell lung cancer$0
I01 · FY2022 · VA · contact PI
Early detection of metastatic disease in US Veterans following surgery for early stage lung cancer$0
I01 · FY2022 · VA · contact PI
UCLA Clinical Translational Science Institute$6,271,504
UL1 · FY2021 · TR · contact PI
UCLA Tumor Immunology Institutional Traning Grant$569,019
T32 · FY2021 · CA
Novel Computation Methods for the Analysis of Cell-Free DNA Sequence Data$552,176
R01 · FY2021 · CA
UCLA Pulmonary and Critical Care Medicine Training Program$544,458
T32 · FY2021 · HL · contact PI
The Boston University-UCLA Lung Cancer Biomarker Development Lab$216,625
U01 · FY2021 · CA
Integrated Molecular, Cellular, and Imaging Characterization of NLST detected lung cancer$156,000
U01 · FY2021 · CA · contact PI
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy$100,000
U2C · FY2021 · CA
Clinically Actionable Neoantigens in Non-Small Cell Lung Cancer$0
I01 · FY2021 · VA · contact PI
Early detection of metastatic disease in US Veterans following surgery for early stage lung cancer$0
I01 · FY2021 · VA · contact PI
Exosome-mediated mechanisms of metastatic disease in non-small cell lung cancer$0
I01 · FY2021 · VA · contact PI
UCLA Clinical Translational Science Institute$9,648,639
UL1 · FY2020 · TR · contact PI
Integrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung Cancer$624,935
U01 · FY2020 · CA · contact PI
Novel Computation Methods for the Analysis of Cell-Free DNA Sequence Data$552,176
R01 · FY2020 · CA
UCLA Pulmonary and Critical Care Medicine Training Program$536,332
T32 · FY2020 · HL · contact PI
UCLA Tumor Immunology Institutional Traning Grant$517,558
T32 · FY2020 · CA
The Boston University-UCLA Lung Cancer Biomarker Development Lab$417,771
U01 · FY2020 · CA
ConProject-001$326,703
UL1 · FY2020 · TR · contact PI
UCLA Clinical Translational Science Institute$234,521
UL1 · FY2020 · TR · contact PI
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy$159,890
U2C · FY2020 · CA
Early detection of metastatic disease in US Veterans following surgery for early stage lung cancer$0
I01 · FY2020 · VA · contact PI
Clinically Actionable Neoantigens in Non-Small Cell Lung Cancer$0
I01 · FY2020 · VA · contact PI
UCLA Clinical Translational Science Institute$10,335,513
UL1 · FY2019 · TR · contact PI
Integrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung Cancer$798,798
U01 · FY2019 · CA · contact PI
Novel Computation Methods for the Analysis of Cell-Free DNA Sequence Data$552,176
R01 · FY2019 · CA
UCLA Tumor Immunology Institutional Traning Grant$535,117
T32 · FY2019 · CA
The Boston University-UCLA Lung Cancer Biomarker Development Lab$516,250
U01 · FY2019 · CA
Clinically Actionable Neoantigens in Non-Small Cell Lung Cancer$0
I01 · FY2019 · VA · contact PI
UCLA Clinical Translational Science Institute$11,300,556
UL1 · FY2018 · TR · contact PI
The Lung PCA: A Multi-Dimensional Atlas of Pulmonary Premalignancy$6,692,860
U2C · FY2018 · CA
Integrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung Cancer$1,218,395
U01 · FY2018 · CA · contact PI
Molecular, Cellular, and Tissue Characterization Unit$1,101,035
U2C · FY2018 · CA · contact PI
The Boston University-UCLA Lung Cancer Biomarker Development Lab$518,499
U01 · FY2018 · CA
UCLA Tumor Immunology Institutional Traning Grant$497,990
T32 · FY2018 · CA
UCLA Clinical Translational Science Institute$494,950
UL1 · FY2018 · TR · contact PI
UCLA Clinical Translational Science Institute$473,903
UL1 · FY2018 · TR · contact PI
A Multi Pilot of a Tool to Assist in Clinical Trial Registration and Reporting$390,000
UL1 · FY2018 · TR · contact PI
Pulmonary and Critical Care Medicine Training Program$207,526
T32 · FY2018 · HL · contact PI
UCLA Clinical Translational Science Institute$207,466
UL1 · FY2018 · TR · contact PI
Clinically Actionable Neoantigens in Non-Small Cell Lung Cancer$0
I01 · FY2018 · VA · contact PI
Cell Motility in the Pathogenesis of Lung Cancer$0
I01 · FY2018 · VA · contact PI
UCLA Clinical Translational Science Institute$13,914,644
UL1 · FY2017 · TR · contact PI
The Boston University-UCLA Lung Cancer Biomarker Development Lab$860,456
U01 · FY2017 · CA
Integrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung Cancer$764,788
U01 · FY2017 · CA · contact PI
Integrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung Cancer$456,656
U01 · FY2017 · CA · contact PI
UCLA Clinical Translational Science Institute$452,432
UL1 · FY2017 · TR · contact PI
UCLA Clinical Translational Science Institute$446,247
UL1 · FY2017 · TR · contact PI
Pulmonary and Critical Care Medicine Training Program$391,515
T32 · FY2017 · HL · contact PI
Cell Motility in the Pathogenesis of Lung Cancer$0
I01 · FY2017 · VA · contact PI
UCLA Clinical Translational Science Institute$14,788,027
UL1 · FY2016 · TR · contact PI
Integrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung Cancer$2,239,851
U01 · FY2016 · CA · contact PI
The Boston University-UCLA Lung Cancer Biomarker Development Lab$565,669
U01 · FY2016 · CA
Pulmonary and Critical Care Medicine Training Program$484,517
T32 · FY2016 · HL · contact PI
UCLA Tumor Immunology Training Program$482,270
T32 · FY2016 · CA
Cell Motility in the Pathogenesis of Lung Cancer$0
I01 · FY2016 · VA · contact PI
Intratumoral genetic therapy for lung cancer$0
I01 · FY2016 · VA · contact PI
UCLA Clinical and Translational Science Institute$14,159,789
UL1 · FY2015 · TR · contact PI
UCLA Clinical and Translational Science Institute$1,216,135
KL2 · FY2015 · TR · contact PI
UCLA Clinical and Translational Science Institute$959,440
TL1 · FY2015 · TR · contact PI
Integrated Molecular, Cellular, and Imaging Characterization of Screen-Detected Lung Cancer$812,527
U01 · FY2015 · CA · contact PI
Pulmonary and Critical Care Medicine Training Program$470,883
T32 · FY2015 · HL · contact PI
UCLA Tumor Immunology Training Program$441,837
T32 · FY2015 · CA
The UCLA - Boston University Lung Cancer Biomarker Development Laboratory$185,509
U01 · FY2015 · CA · contact PI
UCLA Tumor Immunology Training Program$39,503
T32 · FY2015 · CA
Intratumoral genetic therapy for lung cancer$0
I01 · FY2015 · VA · contact PI
Cell Motility in the Pathogenesis of Lung Cancer$0
I01 · FY2015 · VA · contact PI
UCLA Clinical and Translational Science Institute$14,331,847
UL1 · FY2014 · TR · contact PI
UCLA Clinical and Translational Science Institute$1,216,135
KL2 · FY2014 · TR · contact PI
UCLA Clinical and Translational Science Institute$772,589
TL1 · FY2014 · TR · contact PI
The UCLA - Boston University Lung Cancer Biomarker Development Laboratory$598,984
U01 · FY2014 · CA · contact PI
UCLA Tumor Immunology Training Program$467,412
T32 · FY2014 · CA
Pulmonary and Critical Care Medicine Training Program$387,688
T32 · FY2014 · HL · contact PI
UCLA Clinical and Translational Science Institute$113,190
UL1 · FY2014 · TR · contact PI
UCLA Tumor Immunology Training Program$38,799
T32 · FY2014 · CA
Intratumoral genetic therapy for lung cancer$0
I01 · FY2014 · VA · contact PI
UCLA Clinical and Translational Science Institute$13,341,947
UL1 · FY2013 · TR · contact PI
UCLA Clinical and Translational Science Institute$1,217,744
KL2 · FY2013 · TR · contact PI
The UCLA - Boston University Lung Cancer Biomarker Development Laboratory$781,158
U01 · FY2013 · CA · contact PI
The UCLA - Boston University Lung Cancer Biomarker Development Laboratory$593,827
U01 · FY2013 · CA · contact PI
UCLA Clinical and Translational Science Institute$590,853
TL1 · FY2013 · TR · contact PI
UCLA Tumor Immunology Training Program$465,035
T32 · FY2013 · CA
UCLA Tumor Immunology Training Program$38,598
T32 · FY2013 · CA
Intratumoral genetic therapy for lung cancer$0
I01 · FY2013 · VA · contact PI
Inflammation in the pathogenesis of lung cancer$0
I01 · FY2013 · VA · contact PI
UCLA Clinical and Translational Science Institute$15,079,371
UL1 · FY2012 · TR · contact PI
UCLA Clinical and Translational Science Institute$812,366
KL2 · FY2012 · TR · contact PI
The UCLA - Boston University Lung Cancer Biomarker Development Laboratory$783,499
U01 · FY2012 · CA · contact PI
The UCLA - Boston University Lung Cancer Biomarker Development Laboratory$647,222
U01 · FY2012 · CA · contact PI
UCLA Tumor Immunology Training Program$432,554
T32 · FY2012 · CA
UCLA Clinical and Translational Science Institute$417,110
TL1 · FY2012 · TR · contact PI
Pulmonary and Critical Care Medicine Training Program$88,639
T32 · FY2012 · HL · contact PI
UCLA Tumor Immunology Training Program$30,666
T32 · FY2012 · CA
Inflammation in the pathogenesis of lung cancer$0
I01 · FY2012 · VA · contact PI
Intratumoral genetic therapy for lung cancer$0
I01 · FY2012 · VA · contact PI
UCLA Clinical and Translational Science Institute$15,457,370
UL1 · FY2011 · RR · contact PI
CTSA INFRASTRUCTURE FOR CLINICAL TRIALS$7,321,847
UL1 · FY2011 · RR · contact PI
UCLA CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE$4,393,139
UL1 · FY2011 · RR · contact PI
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCH$2,196,647
UL1 · FY2011 · RR · contact PI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH$772,869
UL1 · FY2011 · RR · contact PI
CTSA INFRASTRUCTURE FOR AIDS RESEARCH$772,868
UL1 · FY2011 · RR · contact PI
The UCLA - Boston University Lung Cancer Biomarker Development Laboratory$662,594
U01 · FY2011 · CA · contact PI
UCLA Clinical and Translational Science Institute$406,987
KL2 · FY2011 · RR · contact PI
UCLA Clinical and Translational Science Institute$240,566
TL1 · FY2011 · RR · contact PI
Pulmonary and Critical Care Medicine Training Program$121,919
T32 · FY2011 · HL · contact PI
Thoracic Oncology$36,509
P30 · FY2011 · CA · contact PI
Inflammation in the pathogenesis of lung cancer$0
I01 · FY2011 · VA · contact PI
The UCLA - Boston University Lung Cancer Biomarker Development Laboratory$725,083
U01 · FY2010 · CA · contact PI
Tumor Immunology Institutional Training Grant$411,595
T32 · FY2010 · CA · contact PI
Pulmonary and Critical Care Medicine Training Program$315,309
T32 · FY2010 · HL · contact PI
Novel COX-2 and PGE2-dependent pathways in lung cancer$239,656
R01 · FY2010 · CA · contact PI
Thoracic Oncology$46,489
P30 · FY2010 · CA · contact PI
Pulmonary and Critical Care Medicine Training Program$386,843
T32 · FY2009 · HL · contact PI
Tumor Immunology Institutional Training Grant$383,014
T32 · FY2009 · CA · contact PI
Novel COX-2 and PGE2-dependent pathways in lung cancer$239,656
R01 · FY2009 · CA · contact PI
Novel COX-2 and PGE2-dependent pathways in lung cancer$58,710
R01 · FY2009 · CA · contact PI
Thoracic Oncology$44,106
P30 · FY2009 · CA · contact PI
Inflammation in the pathogenesis of lung cancer$0
I01 · FY2009 · VA · contact PI
Pulmonary and Critical Care Medicine Training Program$383,577
T32 · FY2008 · HL · contact PI
UCLA SPORE IN LUNG CANCER$239,935
P50 · FY2008 · CA · contact PI
Novel COX-2 and PGE2-dependent pathways in lung cancer$239,656
R01 · FY2008 · CA · contact PI
Tumor Immunology Institutional Training Grant$209,005
T32 · FY2008 · CA · contact PI
Novel COX-2 and PGE2-dependent pathways in lung cancer$57,781
R01 · FY2008 · CA · contact PI
UCLA SPORE IN LUNG CANCER$537,211
P50 · FY2007 · CA · contact PI
Tumor Immunology Institutional Training Grant$465,403
T32 · FY2007 · CA · contact PI
Pulmonary and Critical Care Medicine Training Program$375,441
T32 · FY2007 · HL · contact PI
A Phase I Trial of CCL-21 Gene Modified DC in NSCLC$331,634
R21 · FY2007 · CA · contact PI
Novel COX-2 and PGE2-dependent pathways in lung cancer$239,656
R01 · FY2007 · CA · contact PI
Novel COX-2 and PGE2-dependent pathways in lung cancer$32,939
R01 · FY2007 · CA · contact PI
UCLA SPORE IN LUNG CANCER$1,189,000
P50 · FY2006 · CA · contact PI
Tumor Immunology Institutional Training Grant$398,208
T32 · FY2006 · CA · contact PI
Pulmonary and Critical Care Medicine Training Program$375,441
T32 · FY2006 · HL · contact PI
Novel COX-2 and PGE2-dependent pathways in lung cancer$246,814
R01 · FY2006 · CA · contact PI
UCLA SPORE IN LUNG CANCER$2,399,395
P50 · FY2005 · CA
New pathways in IL7 mediated antifibrotic responses$204,345
P50 · FY2005 · HL
UCLA SPORE IN LUNG CANCER$45,738
P50 · FY2005 · CA
UCLA SPORE IN LUNG CANCER$2,405,646
P50 · FY2004 · CA
GENETIC IMMUNOTHERAPY FOR LUNG CANCER$274,500
R01 · FY2004 · CA
UCLA SPORE IN LUNG CANCER$44,127
P50 · FY2004 · CA
UCLA SPORE IN LUNG CANCER$2,397,978
P50 · FY2003 · CA
A Phase I Trial of CCL-21 Gene Modified DC in NSCLC$339,683
R21 · FY2003 · CA
GENETIC IMMUNOTHERAPY FOR LUNG CANCER$274,500
R01 · FY2003 · CA
UCLA SPORE IN LUNG CANCER$28,467
P50 · FY2003 · CA
UCLA SPORE IN LUNG CANCER$2,317,077
P50 · FY2002 · CA
GENETIC IMMUNOTHERAPY FOR LUNG CANCER$274,950
R01 · FY2002 · CA
New pathways in IL7 mediated antifibrotic responses$182,367
P50 · FY2002 · HL
Dendritic cell-based genetic immunotherapy /lung cancer$0
P50 · FY2002 · CA
UCLA SPORE IN LUNG CANCER$1,410,484
P50 · FY2001 · CA
GENETIC IMMUNOTHERAPY FOR LUNG CANCER$275,400
R01 · FY2001 · CA
FUNCTION AND REGULATION OF IL 10 IN LUNG CANCER$121,990
R01 · FY2001 · CA
Dendritic cell-based genetic immunotherapy /lung cancer$0
P50 · FY2001 · CA
New pathways in IL7 mediated antifibrotic responses$0
P01 · FY2001 · HL